Compared with the trial results of EUCLID and PEGASUS, the COMPASS trial advances the field of cardiovascular disease in combination therapies, said John Eikelboom, MD, of McMaster University.
Compared with the trial results of EUCLID and PEGASUS, the COMPASS trial advances the field of cardiovascular disease in combination therapies, said John Eikelboom, MD, of McMaster University.
Transcript (slightly modified)
Can you put the results of the COMPASS trial in perspective compared with the results of the EUCLID and PEGASUS trials?
The recent trials EUCLID and PEGASUS attempted to improve on the existing standard of care by evaluating alternative, more intensive, antithrombotic strategies. If we take EUCLID, this was a trial in patients with peripheral artery disease that evaluated ticagrelor as an alternative to clopidogrel. The EUCLID trial was very important, very large, a well-done study and it showed absolutely no benefit of ticagrelor. Thus, the EUCLID trial didn’t really advance treatment in peripheral artery disease.
The PEGASUS trial was an important, and, again, global, large, well-done study in patients post-myocardial infarction. In this trial, 2 doses of ticagrelor that were tested were on top of aspirin and the results indicate a reduction in major adverse cardiovascular events, an increase in bleeding, and no overall mortality benefit. So, in this context, the results of COMPASS really advanced the field because the combination therapy in COMPASS doesn’t only reduce major adverse cardiovascular events, but also reduces total mortality.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More